<DOC>
	<DOCNO>NCT00685360</DOCNO>
	<brief_summary>This clinical trial evaluate safety efficacy OPC-67683 treatment multidrug resistant tuberculosis ( MDR TB ) 56 day . In addition optimize background regimen ( OBR ) .patients receive randomize : - 100 mg OPC-67683 BID - 200 mg OPC-67683 BID - placebo BID After 56 day subject complete OBR .</brief_summary>
	<brief_title>A Placebo-controlled , Phase 2 Trial Evaluate OPC 67683 Patients With Pulmonary Sputum Culture-positive , Multidrug-resistant Tuberculosis ( TB )</brief_title>
	<detailed_description>This multi center , randomize , double-blinded , stratified , placebo-controlled clinical trial three parallel group . Patients randomize one follow three treatment group : - Optimized Background Regimen ( OBR ) plus 100 mg OPC-67683 twice daily - OBR plus 200 mg OPC-67683 twice daily - OBR plus placebo twice daily The three treatment group comprise approximately 140 patient ( male female ) . The trial consist follow period : - Pre-treatment Period ( Visits 1 3 [ Day -9 Day -1 ] ) - Treatment Period ( Visits 4 59 [ Days 1 56 ] ) - Post-treatment Period ( Visits 60 64 [ Days 57 84 ] ) Enrolled patient ( accepted screening period trial sign informed consent form ) stratify randomization extent pulmonary TB ; equal number patient without cavity visible lung field baseline chest radiograph allocate treatment group . A total 430 male female patient age 18 64 year , inclusive , pulmonary , sputum culture-positive MDR TB ( TB cause Mycobacterium tuberculosis strain resistant least isoniazid rifampicin ) sputum smear positive acid fast bacillus ( AFB ) positive rapid test rifampicin resistance direct sputum within 60 day prior expect date enrollment . Patients positive AFB smear positive rapid rifampicin resistance test enrol presumptively culture positive withdrawn ineligible confirm sputum culture positive MDR TB .</detailed_description>
	<mesh_term>Tuberculosis</mesh_term>
	<mesh_term>Tuberculosis , Multidrug-Resistant</mesh_term>
	<mesh_term>Tuberculosis , Pulmonary</mesh_term>
	<mesh_term>Extensively Drug-Resistant Tuberculosis</mesh_term>
	<criteria>Provide write , informed consent prior trialrelated procedure Male female patient age 18 64 year , inclusive . Either mycobacterial culture sputum positive growth M. tuberculosis sputum smear positive acid fast bacilli within 60 day prior expect date enrollment . Patient TB cause isolates M. tuberculosis complex confirm resistant treatment isoniazid rifampicin , positive rapid test rifampicin resistance direct sputum positive acid fast bacilli within 60 day prior expect date enrollment . Findings chest radiograph consistent TB . Able produce sputum mycobacterial culture . Female patient childbearing potential must negative urine pregnancy test agree use highly effective method birth control ( example , two follow precaution : tubal ligation , vaginal diaphragm , intrauterine device , oral contraceptive , contraceptive implant , combine hormonal patch , combine injectable contraceptive depotmedroxyprogesterone acetate ) throughout participation trial 22 week last dose ( cover duration ovulation ) . Male patient must agree use adequate method contraception ( double barrier ) throughout participation trial 30weeks last dose ( cover duration spermatogenesis ) . A history allergy nitroimidazoles nitroimidazole derivates time . Use medication Section 4.1 protocol include : use amiodarone time previous 12 month , use antiarrhythmic previous 30 day , use certain medication , include certain antidepressant , antihistamine , macrolides , previous 14 day . Any current serious concomitant condition renal impairment characterize serum creatinine level â‰¥265 micromol/L hepatic impairment characterize ALT and/or aspartate transferase ( AST ) level 3 time upper limit laboratory reference range . Current clinically relevant change ECG atrioventricular ( AV ) block , prolongation QRS complex 120 millisecond ( male female patient ) , either QTcF QTcB interval 430 millisecond male patient 450 millisecond female patient . Current clinically relevant cardiovascular disorder heart failure , coronary heart disease , hypertension , arrhythmia , tachyarrhythmia status myocardial infarction . For patient HIV infection , CD4 cell count &lt; 350/mm3 treatment antiretroviral medication HIV infection . Karnofsky score &lt; 60 % . Any disease condition use nitroimidazoles nitroimidazole derivates contraindicate . Evidence clinically significant metabolic , gastrointestinal , neurological , psychiatric endocrine disease , malignancy , abnormality ( indication study ) . Known suspected alcohol abuse , , abuse sufficient enough compromise safety cooperation patient opinion investigator . Administered IMP within 1 month prior Visit 1 ( Screening [ Days 9 3 ] ) . Pregnant , breastfeeding , plan conceive father child within timeframe describe informed consent form . Recent use methadone , benzodiazepine , cocaine , amphetamine/metamphetamine , tetrahydrocannabinol , barbiturate , tricyclic antidepressant , opiate determine urine drug screen unless evidence provide positive drug screen result authorize medication product prescribe physician non abuse related indication . Any disorder judgment investigator make subject good candidate trial may prevent patient reliably participate entire course trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Tuberculosis</keyword>
	<keyword>Pulmonary</keyword>
	<keyword>Multidrug resistant</keyword>
	<keyword>Antitubercular Agents</keyword>
	<keyword>OPC 67683</keyword>
</DOC>